APA (7th ed.) Citation

Xu, J., Cui, J., Jiang, H., Zeng, Y., & Cong, X. (2023). Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients. Cancer Medicine, 12(7), 7762. https://doi.org/10.1002/cam4.5532

Chicago Style (17th ed.) Citation

Xu, Jianming, Jiuwei Cui, Haiping Jiang, Yan Zeng, and Xiuyu Cong. "Phase 1 Dose Escalation Study of FGFR4 Inhibitor in Combination with Pembrolizumab in Advanced Solid Tumors Patients." Cancer Medicine 12, no. 7 (2023): 7762. https://doi.org/10.1002/cam4.5532.

MLA (9th ed.) Citation

Xu, Jianming, et al. "Phase 1 Dose Escalation Study of FGFR4 Inhibitor in Combination with Pembrolizumab in Advanced Solid Tumors Patients." Cancer Medicine, vol. 12, no. 7, 2023, p. 7762, https://doi.org/10.1002/cam4.5532.